Unravelling the lung cancer diagnostic pathway: identifying gaps and opportunities for improvement

11. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin 2021; 71: 7–33. doi: 10.3322/caac.21654 SiegelRL MillerKD FuchsHE JemalA Cancer statistics, 2021 CA Cancer J Clin 2021 71 7 33 10.3322/caac.21654 Open DOISearch in Google Scholar

12. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019; 144: 1941–53. doi: 10.1002/ijc.31937 FerlayJ ColombetM SoerjomataramI MathersC ParkinDM PinerosM Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods Int J Cancer 2019 144 1941 53 10.1002/ijc.31937 Open DOISearch in Google Scholar

13. Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34: 339–57. doi: 10.1016/j.annonc.2022.12.009 HendriksLE KerrKM MenisJ MokTS NestleU PassaroA Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Ann Oncol 2023 34 339 57 10.1016/j.annonc.2022.12.009 Open DOISearch in Google Scholar

14. Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34: 358–76. doi: 10.1016/j.annonc.2022.12.013 HendriksLE KerrKM MenisJ MokTS NestleU PassaroA Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Ann Oncol 2023 34 358 76 10.1016/j.annonc.2022.12.013 Open DOISearch in Google Scholar

15. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87–108. doi: 10.3322/caac.21262 TorreLA BrayF SiegelRL FerlayJ Lortet-TieulentJ JemalA Global cancer statistics, 2012 CA Cancer J Clin 2015 65 87 108 10.3322/caac.21262 Open DOISearch in Google Scholar

16. Murray PV, O’Brien ME, Sayer R, Cooke N, Knowles G, Miller AC, et al. The pathway study: results of a pilot feasibility study in patients suspected of having lung carcinoma investigated in a conventional chest clinic setting compared to a centralised two-stop pathway. Lung Cancer 2003; 42: 283–90. doi: 10.1016/s0169-5002(03)00358-1 MurrayPV O’BrienME SayerR CookeN KnowlesG MillerAC The pathway study: results of a pilot feasibility study in patients suspected of having lung carcinoma investigated in a conventional chest clinic setting compared to a centralised two-stop pathway Lung Cancer 2003 42 283 90 10.1016/s0169-5002(03)00358-1 Open DOISearch in Google Scholar

17. Copeland J, Neal E, Phillips W, Hofferberth S, Lathan C, Donington J, et al. Restructuring lung cancer care to accelerate diagnosis and treatment in patients vulnerable to healthcare disparities using an innovative care model. MethodsX 2023; 11: 102338. doi: 10.1016/j.mex.2023.102338 CopelandJ NealE PhillipsW HofferberthS LathanC DoningtonJ Restructuring lung cancer care to accelerate diagnosis and treatment in patients vulnerable to healthcare disparities using an innovative care model MethodsX 2023 11 102338 10.1016/j.mex.2023.102338 Open DOISearch in Google Scholar

18. Dunn J, Garvey G, Valery PC, Ball D, Fong KM, Vinod S, et al. Barriers to lung cancer care: health professionals’ perspectives. Support Care Cancer 2017; 25: 497–504. doi: 10.1007/s00520-016-3428-3 DunnJ GarveyG ValeryPC BallD FongKM VinodS Barriers to lung cancer care: health professionals’ perspectives Support Care Cancer 2017 25 497 504 10.1007/s00520-016-3428-3 Open DOISearch in Google Scholar

19. Kutubudin F, Robinson R, Deus P, Hughes K, Wight AG. Impact of national optimal lung cancer pathway – can we meet the 28 day standard by 2020? [abstract]. Thorax 2018; 73(Suppl 4): A140. doi: 10.1136/thorax-2018-212555.229 KutubudinF RobinsonR DeusP HughesK WightAG Impact of national optimal lung cancer pathway – can we meet the 28 day standard by 2020? [abstract] Thorax 2018 73 Suppl 4 A140 10.1136/thorax-2018-212555.229 Open DOISearch in Google Scholar

20. Jaly A, Conroy S, Mohsin N. Implementing the National Optimal Lung Cancer Pathway; STHK experience. European Congress of Radiology - ECR 2020; Poster: C-12308. [Internet]. Available at: https://dx.doi.org/10.26044/ecr2020/C-12308. doi: 10.26044/ecr2020/C-12308 JalyA ConroyS MohsinN Implementing the National Optimal Lung Cancer Pathway; STHK experience European Congress of Radiology - ECR 2020 Poster: C-12308. [Internet]. Available at: https://dx.doi.org/10.26044/ecr2020/C-12308. 10.26044/ecr2020/C-12308 Open DOISearch in Google Scholar

21. Fung-Kee-Fung M, Maziak DE, Pantarotto JR, Smylie J, Taylor L, Timlin T, et al. Regional process redesign of lung cancer care: a learning health system pilot project. Curr Oncol 2018; 25: 59–66. doi: 10.3747/co.25.3719 Fung-Kee-FungM MaziakDE PantarottoJR SmylieJ TaylorL TimlinT Regional process redesign of lung cancer care: a learning health system pilot project Curr Oncol 2018 25 59 66 10.3747/co.25.3719 Open DOISearch in Google Scholar

22. Jacobsen MM, Silverstein SC, Quinn M, Waterston LB, Thomas CA, Benneyan JC, et al. Timeliness of access to lung cancer diagnosis and treatment: a scoping literature review. Lung Cancer 2017; 112: 156–64. doi: 10.1016/j.lungcan.2017.08.011 JacobsenMM SilversteinSC QuinnM WaterstonLB ThomasCA BenneyanJC Timeliness of access to lung cancer diagnosis and treatment: a scoping literature review Lung Cancer 2017 112 156 64 10.1016/j.lungcan.2017.08.011 Open DOISearch in Google Scholar

23. Rankin NM, York S, Stone E, Barnes D, McGregor D, Lai M, et al. Pathways to lung cancer diagnosis: a qualitative study of patients and general practitioners about diagnostic and pretreatment intervals. Ann Am Thorac Soc 2017; 14: 742–53. doi: 10.1513/AnnalsATS.201610-817OC RankinNM YorkS StoneE BarnesD McGregorD LaiM Pathways to lung cancer diagnosis: a qualitative study of patients and general practitioners about diagnostic and pretreatment intervals Ann Am Thorac Soc 2017 14 742 53 10.1513/AnnalsATS.201610-817OC Open DOISearch in Google Scholar

24. Ost DE, Yeung SCJ, Tanoue LT, Gould MK. Clinical and organizational factors in the initial evaluation of patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143(5 Suppl): e121S–41S. doi: 10.1378/chest.12-2352 OstDE YeungSCJ TanoueLT GouldMK Clinical and organizational factors in the initial evaluation of patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines Chest 2013 143 5 Suppl e121S 41S 10.1378/chest.12-2352 Open DOISearch in Google Scholar

25. Kanashiki M, Satoh H, Ishikawa H, Yamashita YT, Ohtsuka M, Sekizawa K. Time from finding abnormality on mass-screening to final diagnosis of lung cancer. Oncol Rep 2003; 10: 649–52. doi: 10.3892/or.10.3.649 KanashikiM SatohH IshikawaH YamashitaYT OhtsukaM SekizawaK Time from finding abnormality on mass-screening to final diagnosis of lung cancer Oncol Rep 2003 10 649 52 10.3892/or.10.3.649 Open DOISearch in Google Scholar

26. Kashiwabara K, Koshi S, Itonaga K, Nakahara O, Tanaka M, Toyonaga M. Outcome in patients with lung cancer found on lung cancer mass screening roentgenograms, but who did not subsequently consult a doctor. Lung Cancer 2003; 40: 67–72. doi: 10.1016/s0169-5002(02)00505-6 KashiwabaraK KoshiS ItonagaK NakaharaO TanakaM ToyonagaM Outcome in patients with lung cancer found on lung cancer mass screening roentgenograms, but who did not subsequently consult a doctor Lung Cancer 2003 40 67 72 10.1016/s0169-5002(02)00505-6 Open DOISearch in Google Scholar

27. Salomaa ER, Sallinen S, Hiekkanen H, Liippo K. Delays in the diagnosis and treatment of lung cancer. Chest 2005; 128: 2282–8. doi: 10.1378/chest.128.4.2282 SalomaaER SallinenS HiekkanenH LiippoK Delays in the diagnosis and treatment of lung cancer Chest 2005 128 2282 8 10.1378/chest.128.4.2282 Open DOISearch in Google Scholar

28. Saint-Jacques N, Rayson D, Al-Fayea T, Virik K, Morzycki W, Younis T. Waiting times in early-stage non-small cell lung cancer (NSCLC). J Thorac Oncol 2008; 3: 865–70. doi: 10.1097/JTO.0b013e318180210c Saint-JacquesN RaysonD Al-FayeaT VirikK MorzyckiW YounisT Waiting times in early-stage non-small cell lung cancer (NSCLC) J Thorac Oncol 2008 3 865 70 10.1097/JTO.0b013e318180210c Open DOISearch in Google Scholar

29. Risberg T, Sorbye SW, Norum J, Wist EA. Diagnostic delay causes more psychological distress in female than in male cancer patients. Anticancer Res 1996; 16: 995–9. PMID: 8687166. RisbergT SorbyeSW NorumJ WistEA Diagnostic delay causes more psychological distress in female than in male cancer patients Anticancer Res 1996 16 995 9 8687166 Search in Google Scholar

30. Malalasekera A, Nahm S, Blinman PL, Kao SC, Dhillon HM, Vardy JL. How long is too long? A scoping review of health system delays in lung cancer. Eur Respir Rev 2018; 27: 180045. doi: 10.1183/16000617.0045-2018 MalalasekeraA NahmS BlinmanPL KaoSC DhillonHM VardyJL How long is too long? A scoping review of health system delays in lung cancer Eur Respir Rev 2018 27 180045 10.1183/16000617.0045-2018 Open DOISearch in Google Scholar

31. Neal RD, Robbe IJ, Lewis M, Williamson I, Hanson J. The complexity and difficulty of diagnosing lung cancer: findings from a national primary-care study in Wales. Prim Health Care Res Dev 2015; 16: 436–49. doi: 10.1017/S1463423614000516 NealRD RobbeIJ LewisM WilliamsonI HansonJ The complexity and difficulty of diagnosing lung cancer: findings from a national primary-care study in Wales Prim Health Care Res Dev 2015 16 436 49 10.1017/S1463423614000516 Open DOISearch in Google Scholar

32. Al Achkar M, Zigman Suchsland M, Walter FM, Neal RD, Goulart BHL, Thompson MJ. Experiences along the diagnostic pathway for patients with advanced lung cancer in the USA: a qualitative study. BMJ Open 2021; 11: e045056. doi: 10.1136/bmjopen-2020-045056 Al AchkarM Zigman SuchslandM WalterFM NealRD GoulartBHL ThompsonMJ Experiences along the diagnostic pathway for patients with advanced lung cancer in the USA: a qualitative study BMJ Open 2021 11 e045056 10.1136/bmjopen-2020-045056 Open DOISearch in Google Scholar

33. White V, Bergin RJ, Thomas RJ, Whitfield K, Weller D. The pathway to diagnosis and treatment for surgically managed lung cancer patients. Fam Pract 2020; 37: 234–41. doi: 10.1093/fampra/cmz064.z WhiteV BerginRJ ThomasRJ WhitfieldK WellerD The pathway to diagnosis and treatment for surgically managed lung cancer patients Fam Pract 2020 37 234 41 10.1093/fampra/cmz064.z Open DOISearch in Google Scholar

34. Dunican E, Uzbeck M, Clince J, Toner S, Royston D, Logan MP, et al. Outcomes of patients presenting to a dedicated rapid access lung cancer clinic. Ir Med J 2011; 104: 265–8. PMID: 22132593 DunicanE UzbeckM ClinceJ TonerS RoystonD LoganMP Outcomes of patients presenting to a dedicated rapid access lung cancer clinic Ir Med J 2011 104 265 8 22132593 Search in Google Scholar

35. Aasebo U, Strom HH, Postmyr M. The Lean method as a clinical pathway facilitator in patients with lung cancer. Clin Respir J 2012; 6:169–74. doi: 10.1111/j.1752-699X.2011.00271.x AaseboU StromHH PostmyrM The Lean method as a clinical pathway facilitator in patients with lung cancer Clin Respir J 2012 6 169 74 10.1111/j.1752-699X.2011.00271.x Open DOISearch in Google Scholar

36. Hueto Pérez De Heredia J, Cebollero Rivas P, Cascante Rodrigo JA, Andrade Vela I, Pascal Martínez I, Boldú Mitjans J, et al. Evaluation of the use of a rapid diagnostic consultation of lung cancer. Delay time of diagnosis and therapy. Arch Bronconeumol 2012; 48: 267–73. doi: 10.1016/j.arbr.2012.06.003 Hueto Pérez De HerediaJ Cebollero RivasP Cascante RodrigoJA Andrade VelaI Pascal MartínezI Boldú MitjansJ Evaluation of the use of a rapid diagnostic consultation of lung cancer. Delay time of diagnosis and therapy Arch Bronconeumol 2012 48 267 73 10.1016/j.arbr.2012.06.003 Open DOISearch in Google Scholar

37. Lo DS, Zeldin RA, Skrastins R, Fraser IM, Newman H, Monavvari A, et al. Time to treat: a system redesign focusing on decreasing the time from suspicion of lung cancer to diagnosis. J Thorac Oncol 2007; 2: 1001–6. doi: 10.1097/JTO.0b013e318158d4b6 LoDS ZeldinRA SkrastinsR FraserIM NewmanH MonavvariA Time to treat: a system redesign focusing on decreasing the time from suspicion of lung cancer to diagnosis J Thorac Oncol 2007 2 1001 6 10.1097/JTO.0b013e318158d4b6 Open DOISearch in Google Scholar

38. Murphy DR, Wu L, Thomas EJ, Forjuoh SN, Meyer AN, Singh H. Electronic trigger-based intervention to reduce delays in diagnostic evaluation for cancer: a cluster randomized controlled trial. J Clin Oncol 2015; 33: 3560–7. doi: 10.1200/JCO.2015.61.1301 MurphyDR WuL ThomasEJ ForjuohSN MeyerAN SinghH Electronic trigger-based intervention to reduce delays in diagnostic evaluation for cancer: a cluster randomized controlled trial J Clin Oncol 2015 33 3560 7 10.1200/JCO.2015.61.1301 Open DOISearch in Google Scholar

39. Triller N, Bereš V, Rozman A. [Delays in the diagnosis and treatment of lung cancer: can the period between the onset of symptoms and the diagnosis and treatment be shortened?] [Slovenian]. [Internet]. Zdrav Vestn 2010; 79: 618–22. [cited 2020 Jan 10]. Available from: https://vestnik.szd.si/index.php/ZdravVest/article/view/287 TrillerN BerešV RozmanA [Delays in the diagnosis and treatment of lung cancer: can the period between the onset of symptoms and the diagnosis and treatment be shortened?] [Slovenian]. [Internet] Zdrav Vestn 2010 79 618 22 [cited 2020 Jan 10]. Available from: https://vestnik.szd.si/index.php/ZdravVest/article/view/287 Search in Google Scholar

40. Aapro M, Bossi P, Dasari A, Fallowfield L, Gascon P, Geller M, et al. Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives. Support Care Cancer 2020; 28: 4589–12. doi: 10.1007/s00520-020-05539-1 AaproM BossiP DasariA FallowfieldL GasconP GellerM Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives Support Care Cancer 2020 28 4589 12 10.1007/s00520-020-05539-1 Open DOISearch in Google Scholar